{"entity":{"id":"dnadalhr","kind":"trial","name":"DNADalHR","aka":[],"tldr":"A Chinese trial asking whether a blood test after a tablet-based treatment before surgery can safely spare some women with hormone-receptor-positive breast cancer from chemotherapy.","summary":"DNADalHR (NCT06970912) randomises 393 planned women with high-risk HR-positive, HER2-negative early breast cancer to four cycles of taxane-based chemotherapy or of dalpiciclib with an aromatase inhibitor before surgery; adjuvant treatment is then adjusted by ctDNA. The registry describes tumour-informed personalised ctDNA panels of 16 clonal variants from whole-exome sequencing. Primary endpoints are ctDNA clearance after neoadjuvant therapy and three-year event-free survival; primary completion is estimated for December 2029.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT06970912","url":"https://clinicaltrials.gov/study/NCT06970912"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["mrd-testing"],"targets":["cdk4-6"],"drugs":["dalpiciclib"],"companies":[],"institutions":["pku-peoples-hospital"],"pathways":[],"terms":["mrd","ctdna","tumour-informed-assay"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06970912","phase":"2","setting":"High-risk HR-positive, HER2-negative early breast cancer: neoadjuvant dalpiciclib plus an aromatase inhibitor against taxane chemotherapy (1:4 randomisation), with ctDNA status after surgery deciding adjuvant treatment","sponsor":"Peking University People's Hospital","started":"2025-08-01","startedType":"actual","enrolled":393,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/dnadalhr/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"target":[{"id":"cdk4-6","kind":"target","name":"CDK4/6","route":"/targets/cdk4-6/"}],"drug":[{"id":"dalpiciclib","kind":"drug","name":"Dalpiciclib","route":"/drugs/dalpiciclib/"}],"institution":[{"id":"pku-peoples-hospital","kind":"institution","name":"Peking University People's Hospital","route":"/institutions/pku-peoples-hospital/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"tumour-informed-assay","kind":"term","name":"Tumour-informed versus tumour-naive ctDNA assays","route":"/terms/tumour-informed-assay/"}]}}